title: [Osteoporosis treatment].
abstract: The diagnosis threshold of osteoporosis is based on low bone density value. The therapeutic threshold is modulated by clinical risk factors. Denosumad, an antibody raised against RANK-Ligand, is a potent bone resorption inhibitor. Efficacy on the reduction of fracture incidence is well documented with 800 IU of vitamin D and 1 g of calcium per day. Tibolone (Livial) prevents vertebral fractures but increases strokes. Strontium ranelate (Protélos) prevents fractures over 5 years duration even in women older than 80. Native parathormone (84AA) (Préotac), reduces vertebral fractures. Alendronate (Fosavance), monthly oral and trimonthly i.v. Ibandronate (Bonviva) are the new possibilities of treatment with bisphosphonates. Yearly i.v. zoledronate injections prevent any kind of osteoporotic fractures.
authors.affiliation: Service des maladies osseuses, Centre collaborateur de l'OMS pour la prévention de l'ostéoporose, Département de réhabilitation et gériatrie, HUG, Genève. Brigitte.Uebelhart@hcuge.ch
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D003663:Decision Trees; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*